Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

5 in Phase 3

Quick facts

Phase 3 pipeline

A166 · Oncology
A166 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.
Double blind control period A140 · Diabetes
A140 is a small molecule that targets the SGLT2 receptor.
KL-A167 · Oncology
KL-A167 is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
Open single period A140 · Oncology
A140 is a monoclonal antibody targeting CD47.
SKB264
SKB264 is a biopharmaceutical agent in development by Sichuan Kelun-Biotech, currently in phase 3 clinical trials.

Phase 2 pipeline

SKB518

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s pipeline?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has 5 drugs in Phase 3, 1 in Phase 2, 7 in Phase 1. Late-stage candidates include A166, Double blind control period A140, KL-A167, Open single period A140.

Sector hub: All tracked pharma companies